BioTime to Present at Oppenheimer 27th Annual Healthcare Conference
March 20 2017 - 7:00AM
Business Wire
BioTime, Inc. (NYSE MKT: BTX), a clinical-stage
biotechnology company developing and commercializing products
addressing degenerative diseases, today announced that Russell
Skibsted, Chief Financial Officer, will be presenting at the
Oppenheimer 27th Annual Healthcare Conference at the Westin Grand
Central in New York City on March 21, at 3:55 p.m. Eastern
Time.
A webcast of Mr. Skibsted’s presentation at this conference will
be available at
https://www.veracast.com/webcasts/opco/healthcare2017/06110342543.cfm.
Replays of the presentation will be available on BioTime’s website
at www.biotimeinc.com.
About BioTime
BioTime is a clinical-stage biotechnology company focused on
developing and commercializing products addressing degenerative
diseases. Our clinical programs are based on two platform
technologies: pluripotent stem cells and cell/drug delivery
platform technologies. The foundation of our core therapeutic
technology platform is pluripotent cells that are capable of
becoming any of the cell types in the human body. The foundation of
our cell delivery platform is its HyStem® cell and drug delivery
matrix technology. The Company’s current clinical programs are
targeting three primary sectors, aesthetics, ophthalmology and
cell/drug delivery. We also have significant equity holdings in two
publicly traded companies, Asterias Biotherapeutics, Inc.
(“Asterias”) and OncoCyte Corporation (“OncoCyte”), which we
founded and which, until recently, were our majority-owned
consolidated subsidiaries.
BioTime common stock is traded on the NYSE MKT and TASE under
the symbol BTX. For more information, please visit
www.biotimeinc.com or connect with the company on Twitter,
LinkedIn, Facebook, YouTube, and Google+.
Forward-Looking Statements
Certain statements contained in this release are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Statements pertaining to
future financial and/or operating results, future growth in
research, technology, clinical development, and potential
opportunities for BioTime, Inc. and its subsidiaries and
affiliates, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to
statements that contain words such as “will,” “believes,” “plans,”
“anticipates,” “expects,” “estimates”) should also be considered to
be forward-looking statements. Forward-looking statements involve
risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the business of BioTime,
Inc. and its subsidiaries and affiliates, particularly those
mentioned in the cautionary statements found in more detail in the
“Risk Factors” section of its Annual Reports on Form 10-K and
Quarterly Reports on Form 10-Q filed with the SEC (copies of which
may be obtained at www.sec.gov). Subsequent events and developments
may cause these forward-looking statements to change. BioTime
specifically disclaims any obligation or intention to update or
revise these forward-looking statements as a result of changed
events or circumstances that occur after the date of this release,
except as required by applicable law.
To receive ongoing BioTime corporate communications, please
click on the following link to join our email alert list:
http://news.biotimeinc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170320005286/en/
Investor Contact:EVC Group, Inc.Brian Moore,
310-770-0389bmoore@evcgroup.comorMedia
Contact:Gotham Communications, LLCBill Douglass,
646-504-0890bill@gothamcomm.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2023 to Apr 2024